Maintenance of remission after tocilizumab withdrawal in patients with glucocorticoid-dependent polymyalgia rheumatica

IF 11.4 1区医学 Q1 RHEUMATOLOGY

Arthritis & Rheumatology Pub Date : 2025-05-07 DOI:10.1002/art.43221

Baptiste Chevet, Aghiles Souki, Emmanuel Nowak, Guillermo Carvajal-Alegria, Emmanuelle Dernis, Christophe Richez, Marie-Elise Truchetet, Daniel Wendling, Eric Toussirot, Aleth Perdriger, Jacques-Eric Gottenberg, Renaud Felten, Bruno Fautrel, Anne Lohse, Laurent Chiche, Pascal Hilliquin, Catherine Le Henaff, Benjamin Dervieux, Guillaume Direz, Isabelle Chary-Valckenaere, Divi Cornec, Dewi Guellec, Thierry Marhadour, Alain Saraux, Valérie Devauchelle-Pensec

引用次数: 0

Abstract

The SEMAPHORE trial evaluated the efficacy and safety of tocilizumab (TCZ) in glucocorticoid (GC)-dependent polymyalgia rheumatica (PMR). TCZ reduced GC use and disease activity at 24 weeks.

查看原文本刊更多论文

糖皮质激素依赖性风湿性多肌痛患者托珠单抗停药后缓解的维持

SEMAPHORE试验评估了tocilizumab （TCZ）治疗糖皮质激素（GC）依赖性风湿性多肌痛（PMR）的有效性和安全性。24周时，TCZ减少GC使用和疾病活动。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Arthritis & Rheumatology RHEUMATOLOGY-

CiteScore

20.90

自引率

3.00%

发文量

371

期刊介绍： Arthritis & Rheumatology is the official journal of the American College of Rheumatology and focuses on the natural history, pathophysiology, treatment, and outcome of rheumatic diseases. It is a peer-reviewed publication that aims to provide the highest quality basic and clinical research in this field. The journal covers a wide range of investigative areas and also includes review articles, editorials, and educational material for researchers and clinicians. Being recognized as a leading research journal in rheumatology, Arthritis & Rheumatology serves the global community of rheumatology investigators and clinicians.